Product Description
Mechanisms of Action: DDC Inhibitor,DR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Bulgaria | Croatia | Cyprus | Czech | Denmark | Estonia | France | Germany | Hungary | India | Italy | Japan | Lithuania | New Zealand | Norway | Pakistan | Poland | Portugal | Russia | Slovakia | South Africa | Spain | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: NeuroDerm
Company Location: REHOVOT L3 7670203
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Belgium, Czech Republic, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Portugal, Russia, Slovakia, Spain, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 7
Highest Development Phases
Phase 3: Parkinson's Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ND0612H-012 | P2 |
Not yet recruiting |
Parkinson's Disease |
2027-05-23 |
|
ND0612-317 | P3 |
Not yet recruiting |
Parkinson's Disease |
2027-05-06 |
|
2015-005814-31 | P2 |
Active, not recruiting |
Parkinson's Disease |
2025-02-28 |
|
BouNDless | P3 |
Active, not recruiting |
Parkinson's Disease |
2023-05-18 |